canada clinical guidance

Adult hypertension in primary care

A Canadian summary of the 2025 Hypertension Canada primary-care guideline for diagnosis, risk-based treatment and follow-up.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team · Clinical editorial review · reviewed 2026-08-20 · due 2027-08-20
AudienceCanadian primary-care healthcare professionals caring for adults
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the current 2025 threshold and risk-based primary-care pathway, with provincial or territorial implementation where relevant.

Scope of this summary

Adults managed in primary care. Children, pregnancy or trying to conceive, resistant hypertension and nuanced secondary-cause pathways are outside the selected source.
sources for this section:HC 2025

Measure and confirm

  • Use a validated automated device, an appropriate cuff and standardized technique.
  • Base decisions on repeated, optimally measured blood pressure rather than a single casual value.
  • Use out-of-office measurement when appropriate to identify white-coat or masked hypertension.
  • The 2025 primary-care guideline defines hypertension at blood pressure ≥130/80 mm Hg when measured optimally.
sources for this section:HC 2025HC recommendations

Risk-based treatment thresholds

The guideline recommends pharmacologic treatment when blood pressure is ≥140/90 mm Hg. For systolic blood pressure 130–139 mm Hg, medication is recommended when cardiovascular risk is high according to the source pathway.

For adults receiving treatment, the recommended systolic target is <130 mm Hg when tolerated. Apply contraindications, frailty, adverse effects, orthostatic symptoms and individual goals rather than treating the number in isolation.

sources for this section:HC 2025HC recommendations

When medication is indicated

The guideline generally favours low-dose two-drug therapy, ideally in a single-pill combination. Recommended foundational classes include an ACE inhibitor or ARB, a thiazide or thiazide-like diuretic, and a long-acting dihydropyridine calcium-channel blocker.

This summary deliberately omits product selection and dosing. Check contraindications, pregnancy potential, kidney function, electrolytes, interactions, provincial formularies and the complete source.

sources for this section:HC 2025

Follow-up essentials

  • Reassess blood pressure, tolerability and adherence after starting or changing therapy.
  • Review cardiovascular risk and comorbidities rather than using blood pressure alone.
  • Escalate suspected secondary, resistant or urgent presentations to the appropriate pathway.
sources for this section:HC 2025

Older thresholds are stale

The 2025 primary-care guideline changed the Canadian definition to 130/80 mm Hg with optimal measurement. Do not reuse older educational material that presents 140/90 mm Hg as the Canadian diagnostic definition.
sources for this section:HC 2025HC recommendations

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Hypertension CanadaHypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary careCMAJ · DOI 10.1503/cmaj.241770 · published 2025-05-26 · accessed 2026-08-20
    view source
  2. Hypertension CanadaGuidelines: Recommendationslive recommendation page checked 2026-08-20 · accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.